JP2018529698A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018529698A5 JP2018529698A5 JP2018515673A JP2018515673A JP2018529698A5 JP 2018529698 A5 JP2018529698 A5 JP 2018529698A5 JP 2018515673 A JP2018515673 A JP 2018515673A JP 2018515673 A JP2018515673 A JP 2018515673A JP 2018529698 A5 JP2018529698 A5 JP 2018529698A5
- Authority
- JP
- Japan
- Prior art keywords
- ezh2 inhibitor
- smarac4
- ezh2
- inhibitor according
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562233146P | 2015-09-25 | 2015-09-25 | |
| US62/233,146 | 2015-09-25 | ||
| US201562252188P | 2015-11-06 | 2015-11-06 | |
| US62/252,188 | 2015-11-06 | ||
| PCT/US2016/053673 WO2017053930A2 (en) | 2015-09-25 | 2016-09-26 | Method of treating malignant rhabdoid tumor of the ovary (mrto)/small cell cancer of the ovary of the hypercalcemic type (sccoht) with an ezh2 inhibitor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018529698A JP2018529698A (ja) | 2018-10-11 |
| JP2018529698A5 true JP2018529698A5 (https=) | 2019-11-07 |
| JP7013369B2 JP7013369B2 (ja) | 2022-02-15 |
Family
ID=58387531
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018515673A Expired - Fee Related JP7013369B2 (ja) | 2015-09-25 | 2016-09-26 | Ｅｚｈ２阻害剤により卵巣の悪性ラブドイド腫瘍（ｍｒｔｏ）／高カルシウム血症型の卵巣の小細胞癌（ｓｃｃｏｈｔ）を処置するための方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20180296563A1 (https=) |
| EP (1) | EP3352761A4 (https=) |
| JP (1) | JP7013369B2 (https=) |
| KR (1) | KR20180054793A (https=) |
| CN (2) | CN114533880B (https=) |
| AU (2) | AU2016325643B2 (https=) |
| CA (1) | CA2999898A1 (https=) |
| EA (1) | EA201890801A1 (https=) |
| IL (2) | IL258302A (https=) |
| MX (2) | MX2018003663A (https=) |
| SG (1) | SG10201908323TA (https=) |
| WO (1) | WO2017053930A2 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3363B1 (ar) | 2011-04-13 | 2019-03-13 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
| CA2887243C (en) | 2012-10-15 | 2024-04-09 | Epizyme, Inc. | Methods of treating cancer |
| KR20180042356A (ko) | 2015-08-24 | 2018-04-25 | 에피자임, 인코포레이티드 | 암 치료 방법 |
| JP7013369B2 (ja) * | 2015-09-25 | 2022-02-15 | エピザイム，インコーポレイティド | Ｅｚｈ２阻害剤により卵巣の悪性ラブドイド腫瘍（ｍｒｔｏ）／高カルシウム血症型の卵巣の小細胞癌（ｓｃｃｏｈｔ）を処置するための方法 |
| WO2017132518A1 (en) | 2016-01-29 | 2017-08-03 | Epizyme, Inc. | Combination therapy for treating cancer |
| WO2017210395A1 (en) | 2016-06-01 | 2017-12-07 | Epizyme, Inc. | Use of ezh2 inhibitors for treating cancer |
| US20200129519A1 (en) * | 2016-06-08 | 2020-04-30 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
| EP3471830A4 (en) | 2016-06-17 | 2020-02-26 | Epizyme Inc | EZH2 INHIBITORS TO TREAT CANCER |
| JP7324144B2 (ja) * | 2017-02-02 | 2023-08-09 | エピザイム，インコーポレイティド | 癌処置様式 |
| US11642346B2 (en) | 2017-03-31 | 2023-05-09 | Epizyme, Inc. | Combination therapy for treating cancer |
| EP3630080A4 (en) | 2017-06-02 | 2021-03-10 | Epizyme, Inc. | USE OF EZH2 INHIBITORS TO TREAT CANCER |
| WO2019050924A1 (en) | 2017-09-05 | 2019-03-14 | Epizyme, Inc. | POLY THERAPY FOR THE TREATMENT OF CANCER |
| JP2022527296A (ja) * | 2019-03-26 | 2022-06-01 | トランスレイショナル・ドラッグ・ディベロップメント・エルエルシー | 卵巣の悪性ラブドイド腫瘍および卵巣高カルシウム血症型小細胞がんを処置する方法 |
| CN114555112A (zh) * | 2019-08-22 | 2022-05-27 | 朱诺治疗学股份有限公司 | T细胞疗法和zeste增强子同源物2(ezh2)抑制剂的组合疗法及相关方法 |
| CN110960525A (zh) * | 2019-11-26 | 2020-04-07 | 济南大学 | 新型eed-ezh2相互作用抑制剂的确定和评价 |
| CN110950834A (zh) * | 2019-11-26 | 2020-04-03 | 济南大学 | 新型eed-ezh2相互作用小分子抑制剂的确定和评价 |
| AU2021280314A1 (en) * | 2020-05-28 | 2022-12-08 | Epizyme, Inc. | Use of EZH2 inhibitors for treating cancer |
| CN115786261B (zh) * | 2022-11-28 | 2024-12-06 | 复旦大学附属妇产科医院 | 一种卵巢高钙血症型小细胞癌细胞系及其用途 |
| CN119215165B (zh) * | 2023-06-29 | 2026-03-27 | 复旦大学附属妇产科医院 | Plk1抑制剂在制备治疗卵巢高钙血症型小细胞癌的药物中的应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112013005806B1 (pt) * | 2010-09-10 | 2022-05-10 | Epizyme, Inc | Métodos para detectar se um indivíduo é um candidato para o tratamento com ou responsivo a um inibidor de ezh2 e usos terapêuticos do dito inibidor de ezh2 |
| KR20140033384A (ko) * | 2011-05-16 | 2014-03-18 | 울리커 누베르 | 신규한 암 치료제 및 방법 |
| RU2704445C2 (ru) * | 2012-03-12 | 2019-10-28 | Эпизайм, Инк. | Ингибиторы ezh2 человека и способы их применения |
| SG10201608579UA (en) * | 2012-04-13 | 2016-12-29 | Epizyme Inc | Combination therapy for treating cancer |
| CA2887243C (en) * | 2012-10-15 | 2024-04-09 | Epizyme, Inc. | Methods of treating cancer |
| US20140120083A1 (en) * | 2012-11-01 | 2014-05-01 | Infinity Pharmaceuticals, Inc. | Treatment of cancers using pi3 kinase isoform modulators |
| WO2015103431A1 (en) * | 2013-12-31 | 2015-07-09 | Memorial Sloan-Kettering Cancer Center | Compositions and methods for the diagnosis and treatment of ovarian cancers that are associated with reduced smarca4 gene expression or protein function |
| MX382033B (es) * | 2014-03-19 | 2025-03-13 | Infinity Pharmaceuticals Inc | Compuestos heterocíclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma. |
| KR20180042356A (ko) * | 2015-08-24 | 2018-04-25 | 에피자임, 인코포레이티드 | 암 치료 방법 |
| JP7013369B2 (ja) * | 2015-09-25 | 2022-02-15 | エピザイム，インコーポレイティド | Ｅｚｈ２阻害剤により卵巣の悪性ラブドイド腫瘍（ｍｒｔｏ）／高カルシウム血症型の卵巣の小細胞癌（ｓｃｃｏｈｔ）を処置するための方法 |
-
2016
- 2016-09-26 JP JP2018515673A patent/JP7013369B2/ja not_active Expired - Fee Related
- 2016-09-26 CN CN202210048334.0A patent/CN114533880B/zh active Active
- 2016-09-26 EA EA201890801A patent/EA201890801A1/ru unknown
- 2016-09-26 AU AU2016325643A patent/AU2016325643B2/en not_active Ceased
- 2016-09-26 EP EP16849837.6A patent/EP3352761A4/en not_active Withdrawn
- 2016-09-26 WO PCT/US2016/053673 patent/WO2017053930A2/en not_active Ceased
- 2016-09-26 MX MX2018003663A patent/MX2018003663A/es unknown
- 2016-09-26 CA CA2999898A patent/CA2999898A1/en not_active Abandoned
- 2016-09-26 SG SG10201908323T patent/SG10201908323TA/en unknown
- 2016-09-26 KR KR1020187011111A patent/KR20180054793A/ko not_active Ceased
- 2016-09-26 US US15/762,839 patent/US20180296563A1/en not_active Abandoned
- 2016-09-26 CN CN201680063541.6A patent/CN108349958B/zh active Active
-
2018
- 2018-03-22 IL IL258302A patent/IL258302A/en unknown
- 2018-03-23 MX MX2022013390A patent/MX2022013390A/es unknown
-
2019
- 2019-10-04 US US16/593,010 patent/US20200138825A1/en not_active Abandoned
-
2020
- 2020-09-03 US US17/011,132 patent/US20210121470A1/en not_active Abandoned
-
2021
- 2021-02-09 IL IL280760A patent/IL280760A/en unknown
-
2022
- 2022-10-19 AU AU2022256115A patent/AU2022256115A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018529698A5 (https=) | ||
| US20220411389A1 (en) | Compounds and methods for treating cancer | |
| JP6295081B2 (ja) | フラザノベンゾイミダゾールに対する薬物応答のバイオマーカーとしてのアセチル化チューブリンの使用 | |
| JP2018083821A5 (https=) | ||
| JP2017511377A5 (https=) | ||
| JP6270481B2 (ja) | フラザノベンゾイミダゾールに対する薬物応答のバイオマーカーとしてのｇｌｕ−チューブリンの使用 | |
| JP2016539134A5 (https=) | ||
| JP2017510661A5 (https=) | ||
| WO2015173970A1 (ja) | 抗悪性腫瘍剤組成物 | |
| EA201490014A1 (ru) | Модифицированное высвобождение 4-метил-3-[[4-(3-пиридинил)-2-пиримидинил]амино]-n-[5-(4-метил-1h-имидазол-1-ил)-3-(трифторметил)фенил]бензамида, солюбилизированного с использованием органических кислот | |
| JP2020505426A5 (https=) | ||
| JP2015509489A5 (https=) | ||
| JP6302673B2 (ja) | フラザノベンゾイミダゾールに対する薬物応答のバイオマーカーとしてのｂｕｂｒ１の使用 | |
| JP2018522045A5 (https=) | ||
| CN106999541A (zh) | 拟肽大环化合物及其用途 | |
| JP2019511550A5 (https=) | ||
| JP2013506836A (ja) | プロテインキナーゼｃｋ２介在性疾患のｃｋ２阻害剤に対する感受性および反応を予測するバイオマーカー | |
| JP2019527037A5 (https=) | ||
| JP6302674B2 (ja) | フラザノベンゾイミダゾールに対する薬物応答のバイオマーカーとしてのスタスミンの使用 | |
| Gahr et al. | Combination of the deacetylase inhibitor panobinostat and the multi-kinase inhibitor sorafenib for the treatment of metastatic hepatocellular carcinoma-review of the underlying molecular mechanisms and first case report | |
| CN101512343A (zh) | 黑素瘤抑制性活性蛋白（mia）作为在黑素瘤治疗性反应中的早期指示物的应用 | |
| WO2016172191A1 (en) | Compounds, compositions and methods for inhibiting cnksr1 | |
| Haluska et al. | 214 Homologous recombination deficiency (HRD) score and niraparib efficacy in high grade ovarian cancer | |
| JP6682221B2 (ja) | Ｔａｃｃ３阻害剤のスクリーニング方法 | |
| CN109982700A (zh) | 具有外显子14跳跃突变或外显子14跳跃表型的癌症的治疗 |